A Single-blind, Randomized, Unbalanced Crossover Design With 5 Vehicles, 5 Periods, and 5 Sequences, Repeated-doses (With no Ingestion) Study to Assess the Palatability of Eliglustat Prototype Liquid Formulations in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 30 May 2015
At a glance
- Drugs Eliglustat (Primary)
- Indications Gaucher's disease
- Focus Therapeutic Use
- Sponsors Genzyme Corporation; Sanofi
- 10 Jun 2017 Biomarkers information updated
- 26 May 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 21 May 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.